Cargando…

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target

NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Jin-Ping, Rosenberg, Avi Z., Miettinen, Markku M., Lee, Chyi-Chia R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518519/ https://www.ncbi.nlm.nih.gov/pubmed/23243610 http://dx.doi.org/10.4161/onci.21059

Ejemplares similares

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

RIPK3—a predictive marker for personalized immunotherapy?
por: Smola, Sigrun
Publicado: (2015)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy
por: Hamaï, Ahmed, et al.
Publicado: (2011)

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
por: Müller, Dafne
Publicado: (2012)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

Breaking the HxNy outbreak
por: Manikandan, Jayapal, et al.
Publicado: (2010)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
por: Ramachandran, Indu, et al.
Publicado: (2019)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Antagonizing the innate pattern recognition receptor CD204 to improve dendritic cell-targeted cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2012)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Shock block for improved immunotherapy
por: Rao, Aparna, et al.
Publicado: (2012)

Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
por: Chen, Lei L., et al.
Publicado: (2012)

The perfect PTEN – transcriptional regulation by PTEN dictates sarcoma identity
por: Langdon, Casey G., et al.
Publicado: (2021)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response
por: Gorthi, Aparna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_govqp7d4a26c9v646skl3fc15q